Another day, another Relentless team member to introduce our LI family to! Please join us in welcoming Ahmad Jalil. Based in central B.C. (i.e. Prince George), Ahmad has witnessed first hand through both volunteer and academic experiences the challenges associated with accessibility to quality healthcare in remote regions of Canada. He is energized by the possibilities of what data can offer with respect to personalization of care, especially with respect to our seniors. One additional intriguing note to share, Ahmad is a recipient of the Lieutenant Governor’s Medal for Inclusion, Democracy and Reconciliation. We are proud to have him join Team Relentless. Welcome Ahmad!
Relentless Venture Fund
Venture Capital and Private Equity Principals
Vancouver, BC 1,312 followers
Investing in two ends of the healthcare spectrum from prevention & behaviour modification to chronic disease management.
About us
Relentless has an unwavering commitment to invest in the commercialization of disruptive technology, products, and services that optimize access to care and facilitate a robust continuum of care. We invest in leading-edge clinical research and technologies that manage health risk factors and treat chronic conditions. As technology and mission based investors, we are committed to the development of technologies, products and services that both enhance and promote an individual’s ability to stay optimally healthy and active over an entire lifetime. We target investment at the early stage of a business, the ‘start up’ phase. As early stage investors, we influence product and market development, while tapping into the experience of our seasoned advisors and unique North American network to create additional value. Opportunistically, we include development stage businesses for portfolio balance. Investment Sectors: Preventive health, chronic disease management, seniors' health, digital health, corporate wellness, personal nutrition, behaviour modification, mental wellbeing, neurotech, diabetes, cardiovascular disease, mobility, sensor technology, 3D-printing and healthy longevity.
- Website
-
http://www.relentlesspursuitpartners.com
External link for Relentless Venture Fund
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Vancouver, BC
- Type
- Partnership
- Founded
- 2018
- Specialties
- Seed Investor, Chronic Disease Management, Venture Capital, Investment, Mobility, Digital Health Technology, Sport Technology, Healthy Longevity, Medical Devices, Regenerative Medicine, Preventive Medicine, Personalized Care, and Neurotech
Locations
-
Primary
Get directions
1600-925 West Georgia St.
Vancouver, BC V6C 3L2, CA
Employees at Relentless Venture Fund
-
Alison Twiner
Board Member | Advisor| Investor |Marketing, Sales, Operations leadership
-
Isabella Bertold
Impact Investing Professional | Elevating Female Leadership in Sport and Technology
-
Brenda Irwin
Managing General Partner @ Relentless Venture Fund | Health Technology Venture Capital
Updates
-
Join us in welcoming Shreya Bera to Team Relentless!! With deep not for profit experience working with youth through to seniors, having completed research on topics from depression through to racism & micro-aggressions in healthcare, we are honoured that Shreya is spending her summer with us prior to launching her Master of Public Health studies this autumn at Western. WELCOME SHREYA!!
-
-
Major news out from Tamer Mohamed and the Aspect Biosystems team. $73M in combined funding from the federal and provincial governments. It is an extraordinary commitment. Rather thrilled for Relentless to be on this journey with Aspect and team. #chronicdiseasemanagement #diabetes #T1D #liverdisease #3DPrinting #bioprinting #RVFPortfolio https://lnkd.in/gNdw8J6f
We are excited to announce a $200 million partnership with the Governments of Canada and British Columbia to advance development of bioprinted tissue therapeutics. “This significant investment from the Governments of Canada and B.C. sends a strong signal of support for building and integrating the capabilities needed to discover, develop, and clinically manufacture new medicines for people with serious diseases. This is a major step forward on our bold mission to pioneer an entirely new category of regenerative medicine and build an enduring and globally leading biotech that is delivering sustainable, life-changing impact to patients at home and around the world.” - CEO, Tamer Mohamed Learn more: https://lnkd.in/g6TRWgNC
-
-
CEO of Canary Medical Inc., Dr Bill Hunter sharing a snapshot of where the data is taking us with the company's first product . . . potentially predictive of onset as well as disease progression. 'Gait as a #biomarker' 💡 "Gait is like a fingerprint – completely unique to each of us. It is also extremely complex, requiring highly coordinated functioning of our musculoskeletal, nervous, cardiac and respiratory systems." #digitalhealth #medtech #healthcare #preventivehealth #chronicdisease #RVFPortfolio https://lnkd.in/gNTsvztH
Gait as a Biomarker Few things are more “human” than our ability to walk upright. Ever recognize your child at a distance by observing how an otherwise ill-defined figure was walking or running? Gait is like a fingerprint – completely unique to each of us. It is also extremely complex, requiring highly coordinated functioning of our musculoskeletal, nervous, cardiac and respiratory systems. Abnormalities in virtually any body system result in characteristic ambulatory changes that physicians can use to recognize and diagnose numerous medical maladies. The “shuffling gait” of Parkison’s Disease, the “foot drop” of L5 entrapment, Trendelenberg, hemiplegia, and dystonia have been taught to generations of medical students; there are scores of diseases that result in gait pattern changes (see attached figure). Although the clinical knowledge existed, doctors lacked precise tools to reproducibly identify, measure, and quantify pathognomonic gait changes for true “diagnostic” purposes. Gait labs aren’t widely accessible and wearables need to be worn. A recent article describes the use of wearables to diagnose subclinical heart failure (https://lnkd.in/gh5Q66qb) using a combination of activity and gait metrics. That makes perfect sense to me – poor cardiac function changes your exercise tolerance (activity levels) and gait (e.g. claudication). Persona IQ recently passed 10 BILLION data points and thousands of total knee patients are now generating continuous activity data and “gait lab quality” kinematic data several times per day, every day. Our patients are typically of the age where co-morbid conditions known to alter gait kinematics - neurologic (Parkinson’s Disease, ALS), vascular (CVA, Peripheral Vascular Disease / Claudication, DVT), TKA-related (contracture, loosening), infectious (Prosthetic Joint Infection, Septic Arthritis), metabolic (Diabetes, Gout), and respiratory (COPD) disorders – are developing or are already present. For example, statistically, hundreds of PIQ patients must also have diabetes and heart disease. We are hoping to capture, analyze, categorize, and quantify gait changes associated with non-TKA disorders as the PIQ database expands exponentially. Soon, Activity and Precision Gait Analysis could be used for the early diagnosis of a variety of ailments by identifying and quantifying characteristic gait pattern changes; kinematic data analysis could become a new method for evaluating and predicting disease progression. Vital signs, blood tests, and ECG have served that purpose for decades. Gait could become a “biomarker” in much the same way. Someday, your knee might alert your clinician to pending heart issues. We will be asking our doctors and patients to help us discover predictive gait biomarkers in the coming months. Thank you in advance!
-
Congratulations to the entire team at Aspect Biosystems for this recognition and honour from Life Sciences BC - 🎉 Company of the Year! #chronicdiseasemanagement #diabetes #regenerativemedicine #3dprinting #RVFPortfolio https://lnkd.in/gtv6vxKi
Aspect has been named Company of the Year by Life Sciences BC! 🎉 We are incredibly proud and honoured to receive this award, which recognizes "an outstanding company for its leadership and achievements that are significantly strengthening the BC life sciences sector." Congratulations to our fellow 2024 #LSBCawards winners and nominees. We look forward to celebrating with the BC life sciences community at the awards ceremony in September. Learn more: https://buff.ly/4cydHio
-
-
A wonderful 1 minute, 30 second overview and introduction to Relentless portfolio company Modality.AI. #BIO2024 #neurotech #healthtech #digitalhealth #healthcare NIH SEED https://lnkd.in/g66G2bNQ
NIH SEED is proud to share a #BIO2024 article featuring an interview with Modality.AI’s CEO and Founder David "DSO" Suendermann-Oeft. “Today, Modality is used exclusively in clinical trials to help bring new treatments to the market, and enable researchers to better understand diseases, especially in neurology and psychiatry. ... By expanding into healthcare in the future, Modality.AI will help address the urgent need for better neurological and psychiatric care combined with precision medicine.” Many thanks to Biotechnology Innovation Organization's Clary Estes for this excellent write-up! #SBIR #STTR https://lnkd.in/g3zMRgPf
-
Relentless portfolio company Modality.AI is hosting a webinar on June 21st. A fantastic opportunity to listen in on their activity and progress working with partners in clinical trials for #ALS. #webinar #clinicaltrials #neurologicaldisease #digitalhealth #AI https://lnkd.in/g5QqiWHz
Modality Webinar: A Turning Point in ALS Trials - Friday, June 21 at 11 AM PT https://lnkd.in/gwxGEJVv June 21st is the northern hemisphere’s summer solstice – a turning point – and on this day the ALS/MND community undertakes activities to express their hope for a turning point in the search for cause, treatment and cure of ALS/MND. To drive a turnaround in trials for ALS and other neurological diseases we at Modality advocate for new tools that increase understanding of the course of disease and response to treatment. Together with MGH and Everything ALS and more recently Verge Genomics, Modality’s platform is building the most comprehensive audio/visual dataset of people living with ALS. We invite you to join us on Friday, June 21 at 11 AM PT for a 45-minute live webinar in which we will share highlights from our recent publications and discuss advancements in digital endpoints and the potential to accelerate clinical research with special guest Karl Kieburtz, MD, MPH, Co-Founder and Chair of Clintrex, and principal investigator for numerous multi-center trials in neurology. Please register here: A Turning Point in ALS Trials (you'll be prompted to "Sign in with Zoom" or "verify with email"). https://lnkd.in/gwxGEJVv #ALS #clinicaltrials
-
-
We are excited to share this unique summer internship opportunity as we continue to grow. Yes, the turnaround is tight and yes we love referrals. We promise it will be an extraordinary experience to ultimately impact the care of our seniors living in remote communities. Please submit your application by Wednesday, June 12th, 2024, 5pm pacific. Apply Here: https://lnkd.in/gSij2Rkn - Job Title: Summer Intern – Health Technology Venture Capital About Relentless: We are Canada’s only health technology venture capital firm with the unique focus of investing in the most common chronic conditions associated with our aging population. We are early-stage investors, investing in seed to Series A rounds of investment. We favour investment in software enabled medical devices, regenerative medicine, and digital health. Bringing more than two decades of experience as investors in the Canadian Life Sciences ecosystem, our insights are informed and forward looking. Relentless believes diversity drives innovation and inequality leads to missed opportunities. We value all voices and views. Starting with the team, we invite multiple points of view. The more diverse our team, the more unique our Relentless perspective is. The Opportunity: Understanding the current Canadian ecosystem of elder healthcare resources and existing care strategies enabled by technology in remote communities will help guide our future investments. We are looking for a summer intern to lead this analysis, identify opportunities and gaps in resources. This will involve identifying and interviewing stakeholders, and will be aided by strong research and analytical skills. You will be working closely with the Managing Partner and Investment Associate in identifying gaps, opportunities, and potential collaborators across Canada and regionally (in BC) specific to improving access to health technology innovation. Compensation: Contractor; Project Fee Based + Travel Expenses The Ideal Candidate: - You have completed a minimum two years of post-secondary education with excellent standing. - Candidates studying entrepreneurship, business, population health or health sciences are examples of programs that would be a good foundational starting point for the project. - You are comfortable working independently, with a flexible daily structure, and have a proven ability to be adaptive and meet tight timelines. - You have demonstrated excellence in both written and verbal communication. - You have demonstrated analytical and problem-solving skills in a team environment. - You are detail oriented. - You have comfort and confidence in leading interviews with diverse stakeholders. - You have passion for healthcare innovation and entrepreneurship. Bonus Experience: You have worked with a senior population in either a residential or healthcare facility.
-
-
Relentless portfolio company VitaminLab announces their first partnership that includes electronic health record integration with CharmHealth. Seamless. Personalized care. #RVFPortfolio https://lnkd.in/dJrG8Mi3
"Elevating the standard of care for patients." 💖 Superb collaboration to announce . . . VitaminLab partners with CharmHealth. Love how new partner Charm describes the match as intuitive integration. https://lnkd.in/dNG3uhXB #personalizedcare #supplements #EHR #digitalhealth #healthtech Anton Solonnikov Raymond Shih Relentless Venture Fund #RVFPortfolio
CharmHealth Partners With VitaminLab to Streamline Practitioner Workflows and Elevate Their Standard of Care
businesswire.com
-
Congratulations to team Canary Medical Inc. for winning this prestigious award. As summarized by founder and CEO Bill Hunter: "Business awards can be tricky things. One is obviously proud when one's Company receives them, but there are a numerous awards programs out there and it is difficult to put them into context. The Medtech Breakthough Awards are a respected industry program that highlight novel product solutions across the entire industry. Canary Medical Inc.'s Canturio te, the "smart" stem in Persona IQ, is being recognized as the "Best Overall Solution" in a field as broad as all of medtech. This is a great honour. Let's be honest, orthopaedics isn't always the first thing that pops into your mind when one thinks about medtech innovation. The award is fantastic, but it is the journey it represents that matters most. After a decade of building and perfecting the implants, two years constructing the clinical data platform and the analytics behind it, and finally implementing the patient data into clinical workflows, the greatest reward has been witnessing abnormal patient pathways being detected, flagged, and transmitted; clinicians acting on the data, delivering personalized care, patient performance improving, and TKA outcomes enhanced. This was not a "corporate" effort, but one that included engineers, data scientists, Zimmer sales professionals, medical affairs, doctors, care teams, and the patients themselves. Together, they have taken novel activity and kinematic data and turned it into a way to positively impact one the most common surgical procedures in the world. When we consider the potential for gait as a biomarker for countless different disease states, we may have only scratched the surface of what is possible. One of the most exciting projects I have ever been fortunate enough to be associated with. Congratulations to Zimmer Biomet and the many others that have contributed to a journey of true discovery." #MedTech #Healthcare #Healthtech #mobility #orthopaedics #RVFPortfolio https://lnkd.in/geUyn5B3
We're excited to announce our Canturio™ Tibial Extension has been selected as the winner of "Best Overall Medical Device Solution" in the 8th annual MedTech Breakthrough Awards program. Our "smart knee extension" represents our commitment to transforming healthcare by providing reliable and cost-effective data utilized by HCPs to help improve patient outcomes and ultimately lower costs. This prestigious recognition is a testament to our mission. Read about Canary Medical and view the full list of winners: https://lnkd.in/gbg4fHRd
-